Kornimate/medical-research-clean huggingface dataset:
blood sampling for neurochemical and genetic testing

Conditions: Autonomic Nervous System Disease; Healthy; Hypertension; Pheochromocytoma

Summary: this study involves sampling blood from both normal volunteers and patients with diseases known or suspected to involve body chemicals called catecholamines. the blood will be used to establish normal values for plasma levels of catecholamines and related neurochemicals; to test for abnormal neurochemical patterns in patients; and to establish a "bank" of dna from normal volunteers and from patients to be used in future studies about possible alterations of catecholamine-related genes. study participants will report to nih after fasting overnight except for water or noncaloric, noncaffeinated beverages. they must not have taken tylenol for at least 5 days. blood will then be drawn. dna will be extracted and stored in the freezer for future studies.

this project is to allow blood sampling from normal volunteers and patients with dysautonomia, pheochromocytoma, hypertension, or neurogenetic diseases involving catecholaminergic systems. the blood is used to establish normal values for plasma levels of catechols and related neurochemicals; test for abnormal neurochemical patterns in patients; and establish a "bank" of dna samples from normal volunteers and from patients, to be used in future studies about mutations or polymorphisms of catecholamine-related genes.

Eligibility criteria:
inclusion criteria: the subjects are healthy normal volunteers or patients with dysautonomia, pheochromocytoma, hypertension, or neurogenetic diseases involving catecholaminergic systems. children of any age above 4 years may participate. in the case of minors, consent is obtained from an adult who is legally responsible for the subject. exclusion criteria: subjects in whom anatomic or technical factors preclude insertion of an arm intravenous (i.v.) catheter are excluded. normal volunteers taking any prescribed medication are excluded. normal volunteers who smoke cigarettes or consume alcohol daily are excluded.

Keywords: dopamine metanephrine norepinephrine epinephrine catecholamines tyrosine hydroxylase monoamine oxidase phenosulfotransferase sympathetic nervous system normetanephrine
efficacy of chloroquine or hydroxychloroquine in treating pneumonia caused by sars-cov-2 - covid-19

Conditions: COVID; COVID-19; SARS-CoV 2; Coronavirus; Corona Virus Infection

Summary: facing the challenge of finding an efficient treatment for covid-19, the viral pneumonia caused by the coronavirus sars-cov-2, this study intended to test if chloroquine or hydroxychloroquine, two drugs with strong in-vitro antiviral role proven by numerous studies and with a well defined safety profile established, for efficacy in treating covid-19 and improving an ordinal primary outcome composed by a 9-levels scale, which was recomended by the world health organization.

this is a phase 3, pragmatic, multicentric randomized controled trial of efficacy to test the effect of either chloroquine or hydroxychloroquine for 5 days in the recomended dose standardized by brazilian ministry of health. patients were randomized (1:1) using stratified randomization by hospital and severity at the moment of randomization (stipulated by use of mechanical ventilation or not) into two arms: intervention and control. intervention group recieved a loading dose of 900mg of chloroquine or 800mg of hydroxycloroquine in the first day, followed by 450mg of chloroquine of 400mg of hydroxychloroquine. primary and secondary outcomes were evaluated on the 5th, 7th, 10th, 14th, 28th day after randomization. although the outcomes presented in the latest version were updated late on clinicaltrials.org, on october 23, 2020, these outcomes were already present in the trial protocol approved by the brazilian national commission for ethics in research on april 8, 2020 (approval number: 3960331) and amending the protocol, approved by the same national commission on may 25, 2020 (approval number: 4044848)

Eligibility criteria:
inclusion criteria: * adult males and non-pregnant females that accept and sign the informed consent. * hospitalized with covid-19 suspection that has collected the confirmatory test * to have at least one of thes symptoms: fever, coughing, throat ache or runny nose. * to have at least one of these findings: radiological findings that indicates covid-10 (bilatareal ground grass images); o2 saturation lower than 94% without supplementation and crackles in lung auscultation; need of o2 supplementation; need of mechanical ventilation. * female patients must also agree to use efficient counterceptive methods during the evaluation period. exclusion criteria: * patients with psoriasis or other exfoliative disease, porphyria, epilepsy, myasthenia gravis, advanced liver failure or glucose-6-phosphate dehydrogenase deficiency. * alt / ast\> 5 times the upper limit of normal. * severe chronic kidney disease in stage 4 or requiring dialysis (ie, egfr \<30). * pregnancy or breastfeeding. * early transfer to another hospital that is not a study site within 72 hours. * severe heart disease and / or a history of cardiac arrhythmia. * allergy to chloroquine and / or hydroxychloroquine.

Keywords: viral pneumonia coronavirus covid-19 covid sars-cov-2
effectiveness of focal vibration in shoulder pathology

Conditions: Adhesive Capsulitis; Shoulder

Summary: we hypothesize that focal vibration therapy will reduce pain, increase the mobilization of the glenohumeral joint, and will improve functionality in patients with adhesive capsulitis.

the underlying mechanism of focal vibration therapy in individuals with adhesive capsulitis still remains unclear. considering the physiological mechanism of focal vibration therapy, the effect of focal vibration therapy on pain, function, and resting muscle tone in patients with adhesive capsulitis will be evaluated. there are no studies examining the effect of focal vibration therapy on shoulder muscle tone in individuals with adhesive capsulitis.

Eligibility criteria:
inclusion criteria: * patients aged \> 18 years * unilateral adhesive capsulitis of the shoulder * the symptom duration \> 3 months * shoulder pain * the limited glenohumeral joint active range of motion of greater than 50% in at least three specific movements among abduction, flexion, internal rotation, and external rotation exclusion criteria: * previous shoulder surgeries * massive, minor, and major rotator cuff tears * pain and muscle strength loss due to neurological causes * history or presence of malignancy * osteoporosis * diabetes

Keywords: pain, shoulder vibration
vr education in patients undergoing coronary angiography

Conditions: Coronary Arteriosclerosis

Summary: the aim of this study is to compare standard education with vr augmented education in patients undergoing selective coronary angiography.

the aim of this study is to compare standard education (doctor and nurse led) with virtual reality (vr) augmented education in patients prior toa selective coronary angiography. a 360° education video was prepared in the operating theatre and other areas of the hospital to make patients more comfortable with these unfamilliar places. the procedure was explained in details by a doctor and animations were used to help them to visualise the procedure. risks and complications of the procedure were highlited along with the precautionary measures the patient need to take after the procedure. patients coming into the one-day cardilogy unit of podlesi hospital will be randomised into 2 groups: standard education and vr augmented education. the vr group will be then educated using vr and will be given an opportunity to ask a physician more questions if needed. patients will then fill in forms to assess their experience, feelings and knowledge about the procedure. data will be then collected to assess if vr could facilitate patients' education. the investigators believe it could be a useful tool to save time of doctors and nurses which is becoming more and more precious and expensive.

Eligibility criteria:
inclusion criteria: * patients with indication for undergoing coronary angiography exclusion criteria: * visual impairment

Keywords: virtual reality education
control of sinus node tachycardia as an additional therapy in patients with decompensated heart failure

Conditions: Decompensated Heart Failure

Summary: study aims to compare the i(f) inhibitor ivabradine with placebo as strategy of heart rate control in patients with decompensated heart failure (dhf).

sympathetic hyperactivity and consequent increase in heart rate (hr) are physiological responses to low cardiac output in patients with decompensated heart failure (dhf). however, elevated hr may become inappropriate in these patients, increasing myocardial oxygen demand and decreasing diastolic filling time and might lead to hemodynamic deterioration, ventricular dysfunction (tachycardiomyopathy) and clinical deterioration. studies show the elevated hr is a predictor of poor prognosis in dhf. subanalyses of large clinical trials using beta blockers (bbs) demonstrate the adequate control of hr correlates with a better outcome in patients with stable chronic heart failure (hf). however, use of bbs in patients with dhf is limited due to negative inotropic and hypotensive effects of these drugs. as alternative to bbs, ivabradine has shown to increase survival of patients with chronic stable systolic hf. compared to bbs, ivabradine has the advantage of "pure" negative chronotropic effect, no effect on myocardial contractility or peripheral vascular resistance. despite the inhibition of i (f) has been validated as a therapeutic option in patients with stable hf, there are no studies available on this strategy in patients with dhf. we hypothesized that hr control by ivabradine might improve clinical, hemodynamic and neurohormonal parameters in patients with dhf. the aim of this study was to evaluate the efficacy of hr control with ivabradine in patients with dhf.

Eligibility criteria:
inclusion criteria: * sinus node rhythm * hr\> 80 bpm * hospitalization for dhf * ejection fraction ≤ 40% * sign informed consent exclusion criteria: * systolic blood pressure \<85 mmhg * signs of hypoperfusion * dobutamine\>15 mcg/kg/min * acute myocarditis * primary valvular disease requiring surgery * stroke in the last three months * hypertrophic or restrictive cardiomyopathy * sinus node disease * atrial fibrillation or flutter * second or third degree atrio-ventricular blockade * long qt syndrome * severe pulmonary disease * pulmonary embolism in the last three months * need for invasive ventilatory support * septicemia or septic shock * hepatic failure * creatinine \> 2.5 mg/dl * hemodialysis * advanced malignancy * pregnancy or lactation * immunosuppressive therapy * use of cytochrome p450 inhibitors

Keywords: ivabradine heart rate heart failure
factors influencing physiological hyperopia in children

Conditions: Myopia Progression

Summary: the trend of myopia in children and its low age is a major social and public health problem in china. more seriously, retinopathy associated with high myopia has become the number one cause of irreversible blinding eye disease in adults in some parts of china. physiological hyperopia has a protective effect on preventing the onset of myopia, and is one of the strongest predictors of myopia on its own, which is significant in curbing myopia from occurring at a younger age and preventing the development of high myopia before adulthood. however, it is not yet known how the physiological hyperopia changes in childhood, the stage at which the critical inflection point occurs, which key factors lead to the rapid fading of the physiological hyperopia and progression to myopia, and the strength of its effect. in the early stage of the study, the research group established a prospective cohort of preschoolers based on natural population sampling, which included a total of 2109 preschoolers aged 3-6 years from 22 kindergartens in a district in beijing, and completed a 2-year follow-up, obtaining exploratory results on the changing pattern of physiological hyperopia and key influencing factors in younger children. the group will add new samples to the existing whole cohort sampling cohort and adopt the design scheme of prospective nested case-control study to determine the changing trend of fading trajectory of physiological hyperopia in school-age children, key inflection points and key risk factors, so as to provide new techniques for the prevention and control of childhood myopia.


Eligibility criteria:
inclusion criteria: 1. children aged 6-9 years old, male or female; 2. good cooperation in examination; 3. parents cooperate and sign the informed consent form; exclusion criteria: 1. children with a history of drug allergy; 2. pediatric patients with heart disease, cranial trauma or epilepsy, down syndrome, or glaucoma will be excluded from the cohort.
healthy children 2021 study in childcare centers

Conditions: Family Health; Child Health; Sleep; Child; Executive Function; Pediatric Obesity; Dietary Habits

Summary: in portugal, 17.3% of children under 10 years old are overweight and 7.7% are obese. research has shown the implementation of healthy lifestyle promotion programs and obesity prevention, however "best practices" are far from being defined. also, the first five years of life are important for the executive functions development, namely memory, inhibition (including self-regulation) and flexibility, which includes creative thinking, thinking "outside of the box", important in problem solving. the importance of social and emotional dimensions, as well as physical health for the development of cognitive health is consensual, as sleep deprivation, low physical activity, unhealthy food may inhibit the proper development of executive functions. this project aims to evaluate the effectiveness of a healthy lifestyle promotion program on emotional, social and cognitive development and eating habits, sleep and physical activity in children between 12 and 42 months of age. a cluster randomised trial will be developed and 300 children, from 16 childcare centres will be invited to participate. half of the childcare centres will be allocated to the control group and the other half to the intervention group. data collection will occur before randomisation (at baseline) and after intervention. a feasibility study will be undertaken prior to the experimental study, in accordance with internationally accepted procedures. the investigators intend to implement the concept that the development of executive functions requires the combination of healthy eating, physical activity and sleep. the project will contribute with evidence-based to the cognitive, social and emotional development in children.


Eligibility criteria:
inclusion criteria: * apparently healthy (with no pre-existing conditions) children aged 12-42 months at baseline. exclusion criteria: * children with disability
comparing forearm and upper arm combi cast for distal forearm fractures in children

Conditions: Salter-Harris Type I; Salter-Harris Type 2; Radius Fractures; Forearm Fracture

Summary: the standard treatment for children with closed reduction of displaced distal forearm fractures is an immobilization with an upper arm combicast. the hypothesis is that an forearm immobilization with combicast in children 4-16 years might be sufficient.

children with distal radial or forearm fractures needing closed reduction are eligible for this study. by drawing lots either an immobilization with an upper arm or forearm combicast will be performed. regular controls after 5, 10, 28 days, 4 weeks and 7 weeks will be performed to check the rate of displacement, consolidation time, wearing comfort and movement of the elbow joint after taking off the cast.

Eligibility criteria:
inclusion criteria: * open growth zone * displaced metaphyseal radial or forearm fractures including salter harris fracture 1 and 2 which require closed reduction * written informed consent exclusion criteria: * intraarticular fractures * open fractures * unstable fractures

Keywords: cast, fracture, immobilization, displacement, child
tap block in laparoscopic cholecystectomy.

Conditions: Postoperative Pain

Summary: ultrasound-guided transversus abdominis plane block is now widely used in abdominal surgery. recently, magnesium sulphate is used as adjuvant to local anesthetics.

a significant pain experienced by patients after laparoscopic cholecystectomy surgery is required so as to block nociceptive transmission from both the abdominal wall incision, and visceral sites. using of opioids can result in significant adverse effects, thus delaying early mobilization of patients. ultrasound-guided transversus abdominis plane (tap) block has been used as a satisfactory approach that provides postoperative analgesia. tap block is safe; it diminishes or replaces the use of opioids; and it has a lower incidence of adverse effects. bupivacaine is a medication used to decrease feeling in a specific area. it is used by injecting it into the area, around a nerve that supplies the area, or into the spinal canal's epidural space. bupivacaine is indicated for local infiltration, peripheral nerve block, sympathetic nerve block, and epidural and caudal blocks. magnesium is the fourth most plentiful cation in our body. it may be worthwhile to further study the role of supplemental magnesium in providing perioperative analgesia, because this is a relatively harmless molecule, is not expensive and also because the biological basis for its potential antinociceptive effect is promising. magnesium sulphate (mgso4), n-methyl-d-aspartate receptor antagonist has the potential to be an ideal adjuvant in tap block.

Eligibility criteria:
inclusion criteria: * adult patients (age: 18-65 years old) undergoing laparoscopic cholecystectomy. exclusion criteria: * patient refusal * patients with a history of cardiac, or respiratory diseases ( \>asa iii). * patients with allergy to amide local anesthetics or medication included in the study. * infection at the needle insertion site. * pregnancy * bmi \>35 * drug abusers
vision screening for the detection of amblyopia

Conditions: Amblyopia; Refractive Errors; Anisometropia; Strabismus; Ptosis

Summary: introduction. amblyopia is defined as the loss of visual acuity (va) in one or both eyes, without any obvious structural or pathological anomalies. amblyopic eye should be able to regain some va if treatment is initiated before the age of seven. it is the leading cause of monocular blindness in the 20- to 70-year olds with prevalence 2-5%. amblyopia is mainly monocular, hence children are general asymptomatic. va testing is the only reliable method of detecting amblyopia, and the fourth year of life is considered best for vision screening programs. aim: the purpose of the study is to reduce the preventable vision loss. the main goal of the study is to evidence the problem of amblyopia in zagreb and to release a model for formal, government directed vision-screening program as a croatian public health policy. hypothesis. in croatia, the prevalence and actual effect of amblyopia and amblyogenic factors, along with treatment efficacy is impossible to quantify, since no population-based studies have been performed regarding this issue. in addition, national screening of preschool children does not exist, while the school-entry screening is prescribed by law. the object of the study is to determine the prevalence of amblyopia in a 4-4.5 year old children of the town of zagreb, the efficacy of screening and effectiveness of treatment on reducing amblyopia prevalence. the primary hypothesis is defined: screening of visual acuity monocularly at distance and near in 4-4.5 year old children in zagreb is effective in detecting amblyopia. patients and methods: monocular vision of about 7000 children/ year aged 4-4.5 for whom both parents gave consent is to be tested with lea chart at near (40cm) and distance (3m) in the kindergartens of the town of zagreb. the criterion for referral to complete ophthalmological examination is va \<0.8.


Eligibility criteria:
inclusion criteria: * children in the kindergartens of the town of zagreb aged 4-4.5 for whom both parents gave written informed consent exclusion criteria: * children younger than 4 years and children older than 4.5 years

Keywords: amblyopia amblyogenic factors screening preschool children visual acuity prevalence
identification of markers of poor clinical prognosis in sepsis by epigenetic analysis

Conditions: Sepsis Syndrome; Septic Shock; Sepsis

Summary: sepsis is a multifactorial syndrome characterized by a dynamic course and a clinical outcome dependent on several factors, and responsible for one in five deaths worldwide. the aim of this trial is to identify new prognostic markers for the progression of sepsis to septic shock, by comparing epigenetic markers between patients who have or have not developed severe forms of sepsis. the main objective of this preliminary study is to identify prognostic markers for the progression of sepsis to septic shock, i.e. to compare targeted markers between subjects with sepsis who progress to septic shock versus subjects with sepsis who do not progress to septic shock.


Eligibility criteria:
inclusion criteria: * male patients, * patients between 45 and 75 years of age, * patients undergoing major esophageal or digestive carcinological surgery, * patients with post-operative gram-negative bacterial sepsis (proven or suspected in the context of organ failure). exclusion criteria: * patients under 45 and aged 76 and over, * female patients, * non-carcinological or minor surgery, * non-esophageal or non-digestive surgery, * gram-positive bacterial or fungal infections in the absence of associated bgn, * patients with hematological cancer, * immunocompromised patients, * septic surgery (surgical site infection), * patients expressing opposition to data collection and analysis (clinical and/or biological) within the regulatory framework of the study, * patients under guardianship or curatorship, * patients not affiliated to a social security system or equivalent in france, * patients deprived of their liberty.
screening of microalbuminuria using a semi-quantitative uacr test

Conditions: Diabetes; Microalbuminuria

Summary: microalbuminuria is an important biomarker for the development of diabetic nephropathy and cardiovascular complications. since microalbuminuria is not easily detected on routine urinalysis, current guidelines recommend measuring spot urine albumin-to-creatinine ratio (uacr) annually in a patient with diabetes mellitus. while the standard method is quantitative measurement using turbidimetric immunoassay, it requires high cost and special laboratory equipment. this may be a hurdle that prevents screening for microalbuminuria in many patients with diabetes. therefore, a semi-quantitative uacr test, which is rapid and inexpensive, could be used as a substitute to the current standard quantitative measurement. the investigators aimed to assess the diagnostic accuracy of a semi-quantitative urine albumin-to-creatinine ratio test, uriscan 2acr, as a screening tool for microalbuminuria in patients with diabetes.


Eligibility criteria:
inclusion criteria: * diabetes exclusion criteria: * microscopic hematuria * pyuria * urinary cast